Headquartered in Brisbane, CA·Fiscal year ends December·NASDAQ: ANNX·annexonbio.com
About Annexon
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing targeted immunotherapies against the classical complement pathway for serious neuroinflammatory diseases, which it says affect nearly 10 million people worldwide. Its platform targets C1q, the initiating molecule of the classical complement cascade, aiming to stop complement-driven inflammation, tissue damage and loss of function at its source. The company has no product revenue and funds operations through equity and, as of Q3 2026, a credit facility of up to $200 million with Oxford Finance.
Its pipeline includes:
- **Tanruprubart:** A C1q-targeting antibody for Guillain-Barré syndrome. An EU MAA is under EMA review and a U.S. BLA submission is planned for Q4 2026.
- **Vonaprument:** A C1q-targeting therapy for geographic atrophy, a leading cause of blindness. It is in the global ARCHER II Phase 3 trial, with a Month 15 primary endpoint assessment in Q4 2026.
- **ANX1502:** An oral small-molecule inhibitor of activated C1s for autoimmune diseases, including generalized myasthenia gravis. It is undergoing tablet formulation optimization.
Annexon is building out an ophthalmology commercial franchise ahead of a potential vonaprument launch. Updated
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
Annexon, Inc. (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing targeted immunotherapies against the classical complement pathway for serious neuroinflammatory diseases, which it says affect nearly 10 million people worldwide.
What is the ANNX stock price target?
The Wall Street consensus 12-month price target for ANNX is $17.00.